

Canagliflozin (JNJ-28431754) SDS/MSDS (Safety Data Sheet)

1. PRODUCT AND COMPANY IDENTIFICATION

Product identifier

* Product Name: Canagliflozin (JNJ-28431754)

* Catalog Number: S2760

* CAS Number: 842133-18-0

* IUPAC Name: (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol

Relevant identified uses and uses advised against

* Identified uses: For research and development use only; laboratory chemicals; manufacture of substances.

* Uses advised against: Not for pharmaceutical, household, or other unapproved uses.

Details of the supplier

* Company: Selleck Chemicals

* TollFree: +1 877 796-6397

* Tel: +1 832 582-8158

* Fax: +1 832 582-8590

Emergency telephone number

* Emergency phone #: +1 832 582-8158

2. HAZARDS IDENTIFICATION

2.1 GHS classification in accordance with 29 CFR 1910 (OSHA HCS):

Acute toxicity (oral): Category 4. H302

Serious eye damage: Category 1. H318

Serious eye irritation: Category 2. H319

Reproductive toxicity: Category 2. H361

Reproductive toxicity: Category 1B. H362

Chronic aquatic toxicity: Category 2. H411

2.2 GHS Label elements, including precautionary statements

Hazard Pictogram(s)



Signal Word

Danger

Hazard statement(s)	H302: Harmful if swallowed H318: Causes serious eye damage H319: Causes serious eye irritation H361: Suspected of damaging fertility or the unborn child H362: May cause harm to breast-fed children H411: Toxic to aquatic life with long lasting effects
Precautionary statement(s)	None.
Prevention	P203: Obtain, read and follow all safety instructions before use. P260: Do not breathe dust/fume/gas/mist/vapors/spray. P263: Avoid contact during pregnancy/while nursing. P264: Wash hands thoroughly after handling. P264+P265: Wash hands thoroughly after handling. Do not touch eyes. P270: Do not eat, drink or smoke when using this product. P273: Avoid release to the environment. P280: Wear protective gloves/protective clothing/eye protection/face protection/hearing protection.
Response	P301+P317: IF SWALLOWED: Get medical help. P305+P351: IF IN EYES: Rinse cautiously with water for several minutes. P305+P354: IF IN EYES: Immediately rinse with water for several minutes. P317: Get emergency medical help. P318: if exposed or concerned, get medical advice. P330: Rinse mouth. P337+P317: If eye irritation persists: Get medical help. P338: Remove contact lenses, if present and easy to do. Continue rinsing. P391: Collect spillage.
Storage	P405: Store locked up.
Disposal	P501: P501 Dispose of contents/ container to an approved waste disposal plant.

2.3 Other hazards

None.

3. COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Product name: Canagliflozin (JNJ-28431754)

CAS Number: 842133-18-0

PubChem CID: 24812758

Molecular formula: C₂₄H₂₅FO₅S

Molecular weight: 444.5 g/mol

IUPAC name:

(2S,3R,4R,5S,6R)-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

3.2 Mixtures

Not applicable (pure substance).

4. FIRST-AID MEASURES

4.1 Description of first aid measures

Inhalation: Move to fresh air. Keep at rest in a position comfortable for breathing. Seek medical attention if symptoms persist.

Skin contact: Wash with plenty of soap and water. Remove contaminated clothing. Seek medical attention if irritation develops.

Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing. Seek medical attention.

Ingestion: Rinse mouth. Do NOT induce vomiting unless directed by medical personnel. Seek medical attention.

4.2 Most important symptoms and effects, both acute and delayed

See Section 11 (Toxicological Information).

4.3 Indication of any immediate medical attention and special treatment needed

Treat symptomatically. Contact a poison control center or physician for severe exposure.

5. FIRE-FIGHTING MEASURES

5.1 Extinguishing media

Suitable: Water spray, dry chemical, carbon dioxide (CO₂), alcohol-resistant foam.

Unsuitable: None known.

5.2 Specific hazards arising from the substance or mixture

Suitable Extinguishing Media: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Protective equipment and precautions for firefighters: Wear self-contained breathing apparatus and protective suit.

Wear self contained breathing apparatus for fire fighting if necessary.

5.3 Advice for firefighters

Wear self-contained breathing apparatus (SCBA) and full protective clothing.

Fight fire from upwind. Cool containers with water spray until fire is extinguished.

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Wear appropriate personal protective equipment (see Section 8).

Avoid breathing dust/vapor. Ensure adequate ventilation.

Evacuate personnel to safe areas. Keep people away from and upwind of spill.

6.2 Environmental precautions

Prevent product from entering drains, waterways, or soil.

Contain spill with inert absorbent material.

6.3 Methods and materials for containment and cleaning up

Methods for containment: Prevent further leakage or spillage if safe to do so. Cover powder spill with plastic sheet or tarp to minimize spreading. Dike far ahead of liquid spill for later disposal.

Environmental precautions: Prevent further leakage or spillage if safe to do so. Prevent product from entering drains. Do not flush into surface water or sanitary sewer system.

Methods for cleaning up: Use personal protective equipment as required. Cover powder spill with plastic sheet or tarp to minimize spreading and keep powder dry. Take up mechanically, placing in appropriate containers for disposal. Avoid creating dust. Clean contaminated surface thoroughly. Soak up with inert absorbent material. Dam up. Pick up and transfer to properly labeled containers. Sweep up and shovel into suitable containers for disposal. After cleaning, flush away traces with water. Take precautionary measures against static discharges.

SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

Disposal of wastes: Disposal should be in accordance with applicable regional, national and local laws and regulations.

Contaminated packaging: Do not reuse container.

Personal precautions: Use personal protective equipment as required. Keep people away from and upwind of spill/leak. Evacuate personnel to safe areas.

SRP: Local exhaust ventilation should be applied wherever there is an incidence of point source emissions or dispersion of regulated contaminants in the work area. Ventilation control of the contaminant as close to its point of generation is both the most economical and safest method to minimize personnel exposure to airborne contaminants. Ensure that the local ventilation moves the contaminant away from the worker.

Advice on safe handling: Avoid contact with skin, eyes or clothing. Use personal protective equipment as required. Wash contaminated clothing before reuse. Do not breathe dust/fume/gas/mist/vapors/spray. Do not eat, drink or smoke when using this product. Use with local exhaust ventilation.

7. HANDLING AND STORAGE

7.1 Precautions for safe handling

Storage Conditions: Keep container tightly closed in a dry and well-ventilated place. Keep out of the reach of children. Keep containers tightly closed in a cool, well-ventilated place. Keep in properly labeled containers. Store at -20 degrees C.

7.2 Conditions for safe storage, including any incompatibilities

Storage Conditions: Keep container tightly closed in a dry and well-ventilated place. Keep out of the reach of children. Keep containers tightly closed in a cool, well-ventilated place. Keep in properly labeled containers. Store at -20 degrees C.

Store away from incompatible materials (see Section 10).

[Note: Specific storage temperature not available in public databases. Refer to supplier Certificate of Analysis (COA) for exact storage conditions.]

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Exposure controls

8.1.1 Occupational exposure limits (OEL)

OSHA PEL: Not established.

ACGIH TLV: Not established.

NIOSH REL: Not established.

No occupational exposure limit values are established for this substance.

Use the lowest feasible exposure level (ALARA principle).

8.1.2 Appropriate engineering controls

Use in a well-ventilated area. Chemical fume hood recommended for powder handling.

8.2 Individual protection measures

8.2.1 Eye/face protection

Wear chemical safety goggles and face shield.

8.2.2 Skin protection

Wear protective gloves. Recommended material: Nitrile rubber.

Wear suitable protective clothing (lab coat).

8.2.3 Respiratory protection

Respiratory protection usually not required under normal use with adequate ventilation.

Use N95 respirator for large-scale powder handling.

8.2.4 Thermal hazards

Not applicable.

9. PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

- a) Appearance: Solid powder (typical for research compounds)
- b) Odor: No data available
- c) Odor threshold: No data available
- d) pH: No data available
- e) Melting point/freezing point: 68-72
- f) Initial boiling point and boiling range: 642.9±55.0
- g) Flash point: No data available
- h) Evaporation rate: No data available
- i) Flammability (solid, gas): No data available
- j) Upper/lower flammability or explosive limits: No data available
- k) Vapor pressure: No data available
- l) Vapor density: No data available
- m) Relative density: No data available
- n) Water solubility: almost insoluble
- o) Partition coefficient: n-octanol/water: Log P (n-octanol/water): 3.2
- p) Auto-ignition temperature: No data available
- q) Decomposition temperature: No data available
- r) Viscosity: No data available
- s) Explosive properties: No data available
- t) Oxidizing properties: No data available

9.2 Other information

Topological Polar Surface Area (TPSA): 118 Å²

Complexity: 574

10. STABILITY AND REACTIVITY

10.1 Reactivity

No specific reactivity hazards identified under normal handling conditions.

10.2 Chemical stability

Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions

No hazardous reactions under normal conditions.

10.4 Conditions to avoid

Avoid heat, sparks, open flames, direct sunlight, and moisture.

Avoid strong oxidizing agents, strong acids, and strong bases.

10.5 Incompatible materials

Strong oxidizing agents, strong acids, strong bases.

10.6 Hazardous decomposition products

Thermal decomposition may produce: Carbon monoxide (CO), Carbon dioxide (CO₂), Sulfur oxides (SO_x), Hydrogen fluoride (HF).

See also Section 5 (Fire-fighting measures) for combustion products.

11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute toxicity:

No acute toxicity data available.

Skin corrosion/irritation:

No data available.

Serious eye damage/eye irritation:

Causes serious eye damage (H318).

Respiratory or skin sensitization:

No data available.

Germ cell mutagenicity:

No data available.

Carcinogenicity:

No data available.

Reproductive toxicity:

Suspected of damaging fertility or the unborn child (H361).

Specific target organ toxicity (single exposure):

No data available.

Specific target organ toxicity (repeated exposure):

No data available.

Aspiration hazard:

No data available.

11.2 Additional information

No additional toxicological information available.

12. ECOLOGICAL INFORMATION**12.1 Toxicity**

Canagliflozin's production administration as a medication may result in its release to the environment through various waste streams. If released to air, an estimated vapor pressure of 1.1×10^{-18} mm Hg at 25 °C indicates canagliflozin will exist solely in the particulate phase in the atmosphere. Particulate-phase canagliflozin will be removed from the atmosphere by wet and dry deposition. Canagliflozin does not contain chromophores that absorb at wavelengths >290 nm and, therefore, is not expected to be susceptible to direct photolysis by sunlight. If released to soil, canagliflozin is expected to be immobile based upon an estimated Koc of 6.9×10^4 . Volatilization from moist soil surfaces is not expected to be an important fate process based upon an estimated Henry's Law constant of 1.0×10^{-16} atm-cu m/mole. Canagliflozin is not expected to volatilize from dry soil surfaces based upon its vapor pressure. Biodegradation data in soil or water were not available. If released into water, canagliflozin is expected to adsorb to suspended solids and sediment based upon the estimated Koc. Volatilization from water surfaces is not expected to be an important fate process based upon this compound's estimated Henry's Law constant. An estimated BCF of 120 suggests the potential for bioconcentration in aquatic organisms is high. Hydrolysis is not expected to be an important environmental fate process since this compound lacks functional groups that hydrolyze under environmental conditions (

12.2 Persistence and degradability

No data available.

12.3 Bioaccumulative potential

Log P (n-octanol/water): 3.2

Potential for bioaccumulation exists (Log P > 3).

12.4 Mobility in soil

No data available.

12.5 Results of PBT and vPvB assessment

PBT/vPvB assessment not available.

12.6 Other adverse effects

This substance is classified as hazardous to the aquatic environment.

13. DISPOSAL CONSIDERATIONS**13.1 Waste treatment methods**

Waste Treatment Methods: Waste material must be disposed of in accordance with national and local regulations. Leave chemicals in original containers and do not mix with other waste. Handle uncleaned containers in the same manner as the product itself.

14. TRANSPORT INFORMATION

14.1 UN number

Not regulated as dangerous goods (research quantities typically exempt).

14.2 UN proper shipping name

Not subject to transport regulations (small quantities for research use).

14.3 Transport hazard class(es)

Not classified as dangerous goods for transport (research quantities).

14.4 Packing group

Not applicable (not regulated as dangerous goods in typical research quantities).

14.5 Environmental hazards

Marine pollutant: Yes (classified as environmentally hazardous per GHS).

14.6 Special precautions for user

Transport in original packaging. Ensure containers are tightly sealed.

For bulk or commercial quantities, consult applicable transport regulations (DOT, IATA, IMDG).

14.7 Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable.

15. REGULATORY INFORMATION**15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

US EPA / TSCA: Not available in public databases.

EU ECHA / REACH: Not available in public databases.

SARA 302 Components:

No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

SARA 313 Components:

This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

SARA 311/312 Hazards:

Acute (short-term) health hazard

Chronic (long-term) health hazard

Environmental hazard

Massachusetts Right To Know Components:

This material contains components subject to the Massachusetts Right to Know Act. See Section 2 for hazard classification.

Pennsylvania Right To Know Components:

This material contains components subject to the Pennsylvania Right to Know Act. See Section 2 for hazard classification.

New Jersey Right To Know Components:

This material contains components subject to the New Jersey Right to Know Act. See Section 2 for hazard classification.

California Prop. 65 Components:

This product does not contain any chemicals known to the State of California to cause cancer, birth defects, or any other reproductive harm.

Other regulatory listings:

- FDA Requirements: The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including canagliflozin, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Dextroamphetamine sulfate/

15.2 Chemical safety assessment

A chemical safety assessment has not been carried out for this substance.

For research-use-only compounds, no CSA is required under REACH Annex I.

16. OTHER INFORMATION

Revision Date: 2026/09/09

Further Information: The information provided is believed to be correct but is not exhaustive and should be used only as a guideline based on current knowledge. It does not represent a guarantee of the properties of the product.

Selleck Chemicals Corporation and its Affiliates shall not be held liable for any damage resulting from handling or contact with the product.